Arvinas - ARVN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $59.73
Forecasted Upside: 71.35%
Number of Analysts: 16
Breakdown:
0 Sell Ratings
2 Hold Ratings
14 Buy Ratings
0 Strong Buy Ratings

^$34.86 As of 04/23/2024 01:36 PM ET

▼ -0.04 (-0.11%)

1 month | 3 months | 12 months

Get New Arvinas Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ARVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARVN

^$59.73

▲ +71.35% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $59.73, with a high forecast of $90.00 and a low forecast of $20.00. The average price target represents a 71.35% upside from the last price of $34.86.

Current Consensus is Moderate Buy

The current consensus among 16 polled investment analysts is to moderate buy stock in Arvinas. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/31/2022

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/29/2023

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/29/2023

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/28/2023

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/26/2023

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/24/2024

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/24/2024

0 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/23/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/12/2024	HC Wainwright	Lower Target	Buy ➝ Buy	$90.00 ➝ $87.00	Low
3/25/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$65.00	Low
2/29/2024	Barclays	Boost Target	Overweight ➝ Overweight	$26.00 ➝ $60.00	Low
2/28/2024	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$90.00	Low
2/28/2024	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$89.00 ➝ $90.00	Low
2/28/2024	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$95.00 ➝ $80.00	Low
2/28/2024	Wedbush	Boost Target	Outperform ➝ Outperform	$33.00 ➝ $59.00	Low
2/22/2024	Leerink Partnrs	Reiterated Rating	Outperform		Low
2/14/2024	Citigroup	Downgrade	Buy ➝ Neutral	$36.00 ➝ $55.00	Low
2/1/2024	The Goldman Sachs Group	Initiated Coverage	Buy	$70.00	Low
12/19/2023	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$25.00 ➝ $63.00	Low
12/6/2023	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$32.00 ➝ $40.00	Low
11/20/2023	Guggenheim	Upgrade	Neutral ➝ Buy	$40.00	Low
11/13/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $20.00	Low
11/8/2023	Stifel Nicolaus	Lower Target	Buy ➝ Buy	$46.00 ➝ $42.00	Low
10/24/2023	Citigroup	Lower Target	Buy ➝ Buy	$72.00 ➝ $36.00	Low
10/24/2023	Barclays	Lower Target	Overweight ➝ Overweight	$39.00 ➝ $26.00	Low
10/23/2023	Piper Sandler	Lower Target	Overweight ➝ Overweight	$70.00 ➝ $55.00	Low
10/23/2023	Wedbush	Upgrade	Neutral ➝ Outperform	$27.00 ➝ $24.00	Low
9/7/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$70.00	Low
8/21/2023	Citigroup	Lower Target	Buy ➝ Buy	$77.00 ➝ $72.00	Low
8/16/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$65.00	Low
8/14/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$35.00 ➝ $32.00	Low
8/9/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$90.00	Low
8/9/2023	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$95.00	Low
8/9/2023	Piper Sandler	Lower Target		$81.00 ➝ $70.00	Low
8/8/2023	Barclays	Lower Target	Overweight ➝ Overweight	$70.00 ➝ $39.00	Low
5/8/2023	Stifel Nicolaus	Lower Target		$75.00 ➝ $72.00	Low
3/17/2023	Citigroup	Boost Target		$72.00 ➝ $77.00	Low
2/27/2023	Morgan Stanley	Lower Target	Equal Weight	$57.00 ➝ $36.00	Low
2/24/2023	HC Wainwright	Reiterated Rating	Buy	$90.00	Low
2/24/2023	Credit Suisse Group	Lower Target	Outperform	$81.00 ➝ $61.00	Low
1/31/2023	Cantor Fitzgerald	Reiterated Rating	Overweight	$90.00	Low
1/17/2023	Truist Financial	Lower Target	Buy	$100.00 ➝ $65.00	Low
1/12/2023	Guggenheim	Downgrade	Buy ➝ Neutral		Low
1/10/2023	Wedbush	Lower Target		$43.00 ➝ $27.00	Low
1/10/2023	Oppenheimer	Lower Target		$102.00 ➝ $95.00	Low
1/2/2023	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$83.00 ➝ $49.00	Low
12/5/2022	Citigroup	Lower Target	Buy	$88.00 ➝ $72.00	Low
11/28/2022	The Goldman Sachs Group	Reiterated Rating	Buy	$81.00	Low
11/23/2022	Truist Financial	Lower Target		$170.00 ➝ $100.00	Low
11/23/2022	Cantor Fitzgerald	Lower Target		$106.00 ➝ $90.00	Low
11/23/2022	Barclays	Lower Target	Overweight	$90.00 ➝ $70.00	Low
11/22/2022	Piper Sandler	Boost Target	Overweight	$76.00 ➝ $81.00	Low
11/22/2022	SVB Leerink	Lower Target	Outperform	$89.00 ➝ $74.00	Low
11/15/2022	Credit Suisse Group	Boost Target		$81.00	N/A
11/11/2022	Morgan Stanley	Lower Target	Equal Weight	$63.00 ➝ $57.00	Low
10/25/2022	Capital One Financial	Initiated Coverage	Overweight		Low
10/18/2022	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$80.00	Low
9/21/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
9/9/2022	Barclays	Initiated Coverage	Overweight	$90.00	Low
8/18/2022	Citigroup	Lower Target		$103.00 ➝ $88.00	Low
8/8/2022	Oppenheimer	Lower Target	Outperform	$108.00 ➝ $102.00	Low
8/5/2022	Cantor Fitzgerald	Lower Target		$140.00 ➝ $115.00	Low
8/5/2022	SVB Leerink	Lower Target	Outperform	$91.00 ➝ $89.00	Low
8/5/2022	Credit Suisse Group	Lower Target	Outperform	$98.00 ➝ $78.00	Low
8/5/2022	HC Wainwright	Lower Target	Buy	$135.00 ➝ $90.00	Low
6/21/2022	Jefferies Financial Group	Initiated Coverage	Hold	$42.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$111.00 ➝ $89.00	Low
5/23/2022	Piper Sandler	Lower Target	Overweight	$116.00 ➝ $76.00	High
5/20/2022	Citigroup	Lower Target	Buy	$103.00	Low
5/9/2022	Wedbush	Downgrade	Outperform ➝ Neutral	$43.00	High
5/5/2022	Stifel Europe	Lower Target	Buy ➝ Buy	$85.00 ➝ $82.00	High
4/28/2022	Credit Suisse Group	Initiated Coverage	Outperform	$104.00	High
4/26/2022	Stifel Nicolaus	Lower Target		$93.00 ➝ $85.00	High
4/6/2022	Morgan Stanley	Initiated Coverage	Equal Weight	$65.00	Medium
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		N/A
3/1/2022	Stifel Nicolaus	Lower Target	Buy	$100.00 ➝ $93.00	Medium
3/1/2022	The Goldman Sachs Group	Lower Target	Buy	$157.00 ➝ $110.00	Medium
2/18/2022	Wedbush	Lower Target		$115.00 ➝ $98.00	Low
2/18/2022	SVB Leerink	Lower Target	Outperform	$97.00 ➝ $91.00	Low
2/10/2022	Wells Fargo & Company	Initiated Coverage	Overweight	$98.00	High
1/19/2022	The Goldman Sachs Group	Initiated Coverage	Buy	$157.00	Low
12/6/2021	Cowen	Initiated Coverage	Outperform		Low
11/4/2021	Oppenheimer	Upgrade	Market Perform ➝ Outperform		High
10/14/2021	SVB Leerink	Initiated Coverage	Outperform	$115.00	High
9/29/2021	Stifel Nicolaus	Initiated Coverage	Buy	$115.00	Low
9/9/2021	Bank of America	Initiated Coverage	Buy	$110.00	High
8/9/2021	Roth Capital	Boost Target	Buy	$120.00 ➝ $135.00	Medium
8/5/2021	Piper Sandler	Boost Target	Overweight ➝ Overweight	$105.00 ➝ $125.00	High
7/23/2021	BMO Capital Markets	Boost Target	Outperform	$101.00 ➝ $111.00	High
7/23/2021	Citigroup	Boost Target	Buy	$118.00 ➝ $153.00	High
7/23/2021	HC Wainwright	Reiterated Rating	Buy	$100.00 ➝ $135.00	High
7/23/2021	Oppenheimer	Boost Target	Outperform	$100.00 ➝ $108.00	High
7/22/2021	Piper Sandler	Reiterated Rating	Overweight	$97.00 ➝ $105.00	High
7/22/2021	Truist Financial	Boost Target	Buy	$150.00 ➝ $170.00	High
5/20/2021	UBS Group	Initiated Coverage	Buy	$123.00	High
4/21/2021	Northern Trust Capital Markets	Initiated Coverage	Buy		Low
4/21/2021	Truist Financial	Initiated Coverage	Buy	$150.00	High
3/31/2021	BMO Capital Markets	Initiated Coverage	Outperform	$101.00	High
3/30/2021	Cantor Fitzgerald	Boost Target	Overweight	$121.00 ➝ $140.00	High
1/19/2021	Oppenheimer	Boost Target		$80.00 ➝ $100.00	Low
1/5/2021	Cantor Fitzgerald	Boost Target	Overweight	$66.00 ➝ $121.00	N/A
12/21/2020	Piper Sandler	Boost Target	Overweight	$58.00 ➝ $97.00	Low
12/15/2020	Smith Barney Citigroup	Boost Target		$43.00 ➝ $123.00	High
12/15/2020	Roth Capital	Boost Target	Buy	$65.00 ➝ $120.00	High
12/14/2020	HC Wainwright	Reiterated Rating	Buy	$60.00 ➝ $100.00	High
12/14/2020	BMO Capital Markets	Boost Target	Outperform	$62.00 ➝ $114.00	High
12/14/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform		High
12/14/2020	The Goldman Sachs Group	Boost Target	Buy	$78.00 ➝ $129.00	High
12/14/2020	Wedbush	Boost Target	Outperform	$62.00 ➝ $93.00	High
12/1/2020	Cantor Fitzgerald	Lower Target		$75.00 ➝ $66.00	Medium
10/9/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		High
10/8/2020	Oppenheimer	Reiterated Rating	Hold		High
8/4/2020	Oppenheimer	Initiated Coverage	Hold		Low
6/1/2020	Citigroup	Upgrade	Neutral ➝ Buy	$45.00	Medium
5/31/2020	Oppenheimer	Initiated Coverage	Hold		Low
5/29/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low
5/14/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Medium
5/11/2020	Oppenheimer	Initiated Coverage	Market Perform		Medium
5/4/2020	Roth Capital	Boost Target	Buy	$35.00 ➝ $65.00	High
4/29/2020	HC Wainwright	Reiterated Rating	Buy	$50.00 ➝ $60.00	Medium
4/14/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low
3/16/2020	Piper Sandler	Reiterated Rating	Buy	$58.00	High
1/30/2020	BMO Capital Markets	Reiterated Rating	Outperform	$62.00	High
1/24/2020	Wedbush	Boost Target	Outperform	$39.00 ➝ $60.00	Medium
1/6/2020	Piper Sandler Companies	Boost Target	Overweight	$35.00 ➝ $58.00	N/A
12/20/2019	Cantor Fitzgerald	Boost Target	Overweight	$42.00 ➝ $75.00	Low
12/19/2019	HC Wainwright	Initiated Coverage	Buy	$50.00	High
11/25/2019	Guggenheim	Initiated Coverage	Buy	$50.00	High
11/14/2019	Roth Capital	Initiated Coverage	Buy	$35.00	Medium
11/13/2019	Piper Sandler Companies	Reiterated Rating	Buy	$32.00 ➝ $35.00	High
10/24/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$23.00 ➝ $38.00	Medium
9/24/2019	Wedbush	Initiated Coverage	Outperform	$35.00 ➝ $38.00	Low
9/12/2019	BMO Capital Markets	Initiated Coverage	Outperform	$34.00	High
8/5/2019	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$42.00 ➝ $42.00	Medium
6/5/2019	Citigroup	Downgrade	Buy ➝ Neutral	$21.00 ➝ $22.00	High
5/8/2019	Piper Sandler Companies	Boost Target	Overweight	$23.00 ➝ $32.00	High

(Data available from 4/23/2019 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

9 very positive mentions
1 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/26/2023

1 very positive mentions
4 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

10/26/2023

2 very positive mentions
6 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

11/25/2023

4 very positive mentions
10 positive mentions
4 negative mentions
2 very negative mentions

Mentions as of

12/25/2023

5 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/24/2024

5 very positive mentions
16 positive mentions
6 negative mentions
1 very negative mentions

Mentions as of

2/23/2024

12 very positive mentions
13 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

3/24/2024

9 very positive mentions
6 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

4/23/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Today's Range

Now: $34.86

$34.33

$35.58

50 Day Range

MA: $42.95

$33.44

$52.31

52 Week Range

Now: $34.86

$13.57

$53.08

Volume

166,083 shs

Average Volume

718,990 shs

Market Capitalization

$2.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?: The following Wall Street research analysts have issued reports on Arvinas in the last year: Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Leerink Partnrs, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ARVN.
What is the current price target for Arvinas?: 15 Wall Street analysts have set twelve-month price targets for Arvinas in the last year. Their average twelve-month price target is $59.73, suggesting a possible upside of 71.4%. BMO Capital Markets has the highest price target set, predicting ARVN will reach $90.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $20.00 for Arvinas in the next year.
View the latest price targets for ARVN.
What is the current consensus analyst rating for Arvinas?: Arvinas currently has 2 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARVN.
What other companies compete with Arvinas?: Other companies that are similar to Arvinas include Rhythm Pharmaceuticals, Vera Therapeutics, Rocket Pharmaceuticals, Merus and TG Therapeutics. Learn More about companies similar to Arvinas.
How do I contact Arvinas' investor relations team?: Arvinas' physical mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company's listed phone number is (203) 535-1456 and its investor relations email address is [email protected]. The official website for Arvinas is www.arvinas.com. Learn More about contacing Arvinas investor relations.

Arvinas - ARVN Stock Price Target and Predictions

Analyst Price Target for ARVN

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.91 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?

What is the current price target for Arvinas?

What is the current consensus analyst rating for Arvinas?

What other companies compete with Arvinas?

How do I contact Arvinas' investor relations team?